青光眼治療藥的全球市場(2023年):2022年~2028年的分析
市場調查報告書
商品編碼
1220160

青光眼治療藥的全球市場(2023年):2022年~2028年的分析

2023 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2022 to 2028

出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告提供全球青光眼治療藥市場相關調查,青光眼治療藥市場現狀分析,今後5年的市場效能預測。還有開發平台趨勢,及加入此市場的主要企業的企業簡介等資訊。

目錄

  • 青光眼種類與風險因素
  • 青光眼的診斷和治療
  • 含眼科醫生和驗光師的青光眼照護提供者的世界性見解
  • 全球青光眼的盛行率相關現狀及5年預測
  • 市場上青光眼治療藥與其作用機制
  • 學名藥和品牌藥的比較和對市場的影響
  • 青光眼醫藥品的開發平台
  • 製造、銷售青光眼治療藥的企業的簡介
簡介目錄

The "2023 Glaucoma Pharmaceuticals Market Report" features new regional sales forecasts, market share analysis of generics and branded drugs by drug class in the United States, new analysis of pipeline products, and a summary of ongoing clinical trials. Also included is an updated analysis of the global and regional prevalence of glaucoma and the latest breakdown of diagnosis and treatment paradigms.

SAMPLE VIEW


The report also features new survey data from the United States and Europe, including ophthalmologists' preferences for sustained drug delivery.

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

Coverage includes:

  • Types of glaucoma and risk factors.
  • Diagnosis and treatment of the disease.
  • A global view of glaucoma care providers, including ophthalmologists and optometrists.
  • Current estimates and five-year forecasts for disease prevalence worldwide.
  • Glaucoma medications in the marketplace and their mechanisms of action.
  • Discussion of generic versus branded drugs and their market impact.
  • The development pipeline for glaucoma pharmaceuticals.
  • Profiles of companies making and marketing glaucoma medications.

Author Profile:

Peter Downs

Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.